Tremfya®
(guselkumab)

CHOOSE TREMFYA®, GET TREMFYA®

INDICATIONS

TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported. TREMFYA® may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a clinically important or serious infection develops, discontinue TREMFYA® until infection resolves. Evaluate for tuberculosis before treating with TREMFYA®. Avoid use of live vaccines in patients treated with TREMFYA®. Please see related and other Important Safety Information on last page.

janssen Immunology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson

Tremfya® (guselkumab)

RESOURCES TO HELP YOUR PATIENTS

We are dedicated to helping your patients get started with the TREMFYA® treatment you prescribed. Enrollment starts with you completing

1 FORM

SUPPORT FOR YOUR PATIENTS

In addition, in the midst of current uncertainties surrounding insurance coverage, we want to help your patients understand their coverage options and where Janssen programs may be able to help. Enrollment starts with your patient accepting

1 PHONE CALL 866-889-5660

Scan to add the Wegmans Specialty Pharmacy number to your phone

Please see the Important Safety Information on the last page and the full Prescribing Information.
Provide the Medication Guide to your patients and encourage discussion.

janssen Immunology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

START WITH TREMFYA®
SO SIMPLE TRIAL PROGRAM

The TREMFYA® So Simple Trial Program provides patients their first dose of TREMFYA® so they may determine with their provider if it is right for them.

1 **FORM** for easy enrollment

$0 **COST** to patient

3 Shipment can be authorized within **3 BUSINESS DAYS** after prescription.*

This trial program is open to patients who have commercial insurance, government coverage, or no insurance coverage. However, there is no guarantee of continuous accessibility after the program ends.

*Shipment can be authorized within 3 business days of submitting a prescription pending patient program opt-in and scheduling shipment.

Program is for medication only. Program terms may change.

SUBMIT A COMPLETED PRESCRIPTION ENROLLMENT FORM
(VIA JANSSEN CAREPATH)

Please see the Important Safety Information on the last page and the full Prescribing Information. Provide the Medication Guide to your patients and encourage discussion.

FOR COMMERCIALLY INSURED PATIENTS

STAY ON TREMFYA®

SUBMIT A COMPLETED PRIOR AUTHORIZATION FORM
to the patient's insurance company (via Janssen CarePath or the insurance company directly)

INSURANCE COVERAGE APPROVED

JANSSEN CAREPATH SAVINGS PROGRAM

Eligible patients pay $5 per dose

Maximum program benefit per calendar year shall apply.

See full program requirements at Tremfya.JanssenCarePathSavings.com.

INSURANCE COVERAGE DELAYED >5 BUSINESS DAYS OR DENIED

janssen Link

Janssen Link offers eligible patients TREMFYA® **at no cost** until their commercial insurance covers the medication

See program requirements at **JanssenCarePath.com/Tremfya/Janssen-Link.**

The Janssen CarePath Savings Program and Janssen Link are not valid for patients using Medicare, Medicaid, or other government-funded programs.

Both programs are for medication only. Program terms may change.

PATIENTS NEEDING EXTRA SUPPORT

JANSSEN CAREPATH

can provide information about other resources that may be able to help your patients with their out-of-pocket costs

Have patients visit JanssenCarePath.com for more information about affordability programs that may be available.

For more information about Janssen CarePath, **talk with your Janssen Representative**.

janssen Immunology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM to 8:00 PM ET
Sign Up or Log In to the Provider Portal at JanssenCarePathPortal.com
Visit JanssenCarePath.com

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TREMFYA® (guselkumab) is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Infections

TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Immunizations

Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

ADVERSE REACTIONS

Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

Tremfya® (guselkumab)

janssen Immunology

PHARMACEUTICAL COMPANIES OF Johnson & Johnson